
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is in a strong position to succeed in the clinical development and commercialization of their product candidates, as reflected in the positive feedback from key opinion leaders and the expansion of their collaboration agreement with OPKO Health. Their focus on underserved, chronic medical conditions and potential as a monotherapy treatment makes Entera Bio a promising investment opportunity. However, there are potential risks, including failures in clinical development, competition, and partnership risks, that could impact the achievement of the $10 price target and value of the company.
Bears say
Entera Bio is a clinical-stage biopharmaceutical company that has a negative outlook due to their lack of current product revenue and high losses from changes in fair value of financial liabilities. While the company is developing potential treatments for underserved medical conditions, their limited progress and financial struggles pose a significant risk to their future success. Investors should approach this stock with caution.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares